Phase 2 Non-Alcoholic Fatty Liver Disease Trial, Recruiting (NCT06863376)

Phase 2 Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT06863376 Sponsor: Tanta University Condition: Non-Alcoholic Fatty Liver Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06863376 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Non Alcoholic Fatty Liver Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are an adult (over 18 years old), male or female, and have been diagnosed with fatty liver disease through an abdominal ultrasound scan

Who may not be able to join:

Women who are pregnant or currently breastfeeding
People who drink more than a certain amount of alcohol regularly (more than 30g per day for men, or more than 20g per day for women — confirm with trial site if unsure what this means for you)
People whose liver disease is caused by something other than fatty liver, such as a viral liver infection (like hepatitis B or C), a medication side effect, or an immune system condition affecting the liver
People who have chronic kidney disease, or a condition that causes their parathyroid gland to be overactive or underactive
People who are allergic or have had a bad reaction to a medicine called carbocisteine

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 20 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06863376

Sponsor: Tanta University

Phase: Phase 2

Status: Recruiting

Condition: Non-Alcoholic Fatty Liver Disease

More information: https://clinicaltrials.gov/study/NCT06863376

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are an adult (over 18 years old), male or female, and have been diagnosed with fatty liver disease through an abdominal ultrasound scan

Who may not be able to join:

Women who are pregnant or currently breastfeeding
People who drink more than a certain amount of alcohol regularly (more than 30g per day for men, or more than 20g per day for women — confirm with trial site if unsure what this means for you)
People whose liver disease is caused by something other than fatty liver, such as a viral liver infection (like hepatitis B or C), a medication side effect, or an immune system condition affecting the liver
People who have chronic kidney disease, or a condition that causes their parathyroid gland to be overactive or underactive
People who are allergic or have had a bad reaction to a medicine called carbocisteine

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 20 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Tanta University

Registry

ClinicalTrials.gov

Start date

1 March 2025

Est. completion

20 March 2027

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

The change in the degree of steatosis in the Ultra Sound

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov